SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
DHT Holdings announced entry into an agreement with Hanwha Ocean for construction of a new VLCC vessel scheduled for delivery in August 2028, representing a material capital deployment and fleet expansion decision financed through cash flow, liquidity, and projected mortgage debt.
View raw filing on EDGAR →Austin Gold has filed a National Instrument 43-101 technical report on its Stockade Mountain Project documenting exploration activities, drilling results (including significant gold grades of 8.19 g/t and 9.32 g/t), and identifying new untested drill targets based on geophysical surveys. This material operational disclosure advances the company's core business objective of making district-scale gold discoveries and demonstrates progress on its primary asset.
View raw filing on EDGAR →The 6-K discloses positive Phase 2 clinical trial results for TransCon PTH (palopegteriparatide) in hypoparathyroidism, announced June 11, 2026. The five-year PaTH Forward Trial data demonstrates sustained efficacy and safety with high responder rates (82%), maintained kidney function improvements, and quality-of-life benefits. This is a material clinical milestone for a biopharmaceutical company's lead program, but it is not a discrete event type in the taxonomy (not earnings, M&A, litigation, or other named categories). It is clearly operational—a significant product development and regulatory milestone—making `operational_other` the best fit.
View raw filing on EDGAR →The European Commission approved Sarclisa (isatuximab) subcutaneous formulation administered via an on-body injector for multiple myeloma treatment. This regulatory approval expands the commercial availability and delivery method of the existing marketed drug, representing a material operational and commercial development for Sanofi's oncology portfolio.
View raw filing on EDGAR →Sanofi terminated the MOBILIZE phase 3 clinical trial of riliprubart in CIDP patients following an interim analysis showing insufficient efficacy. The failure of the phase 3 study represents a material setback to the company's pipeline and R&D direction, affecting investor assessment of future revenue potential.
View raw filing on EDGAR →Hydro One announced filing a leave-to-construct application with the Ontario Energy Board for the Durham Kawartha Power Line, a ~$430 million transmission infrastructure investment project expected to be in service in 2029. This is a material operational and strategic business event—a major capital project milestone involving regulatory approval—that does not fit a specific named category. The scale ($430M investment), strategic importance to grid reliability and growth support, and First Nations partnership equity component make this material to investors assessing the company's capital deployment and operational strategy.
View raw filing on EDGAR →Hydro One announced filing a leave-to-construct application with the Ontario Energy Board for the Durham Kawartha Power Line, a ~$430 million transmission infrastructure investment project expected to be in service in 2029. This is a material operational and strategic business event—a major capital project announcement involving regulatory approval—that does not fit a specific named category. The scale ($430M investment), strategic importance (grid reliability and growth support), and First Nations partnership model make this material to investors assessing the company's capital deployment and operational strategy.
View raw filing on EDGAR →Park Ha Biological announced a comprehensive strategic partnership with Star Plus Action (subsidiary of Star Plus Legend Holdings) to build an AI-powered skincare and health ecosystem. The disclosure describes joint development of AI-powered products (AI Nutritionist, AI store managers, AI skincare specialists), resource integration across healthcare, skincare, IP management, and AI technology, and plans for full-chain intelligent service deployment. This is a material operational and strategic business event—a significant partnership and business model expansion—that does not fit the specific categories of M&A activity (no acquisition/merger/change of control), debt issuance, or other named types. It represents a transformative strategic collaboration affecting the company's business direction and competitive positioning.
View raw filing on EDGAR →GSK announced that momelotinib received Orphan Drug Designations (ODD) from the FDA and EMA for VEXAS syndrome treatment, with a planned phase II/III ATLAS trial underway. This is a material regulatory milestone for a rare disease indication that would affect investor assessment of the company's pipeline and development strategy, but it does not fit the specific event categories (not an earnings release, M&A activity, executive change, debt issuance, or other named types). The ODD designation and trial advancement represent a significant operational/strategic development in the drug's regulatory pathway.
View raw filing on EDGAR →